EIF2A and hepatocellular carcinoma: This result was further supported by the finding that combination treatment with capivasertib and an eIF2α inhibitor (ISRIB, SelleckChem, S7400) did not yield synergistic effects in the capivasertib-resistant HCC-1428 cell line (Supplementary Fig. S4).